Ascentage Pharma Group International (HKG:6855) raised $126.4 million from its US initial public offering of 7,325,000 American depository shares at $17.25 apiece, a Tuesday press release said.
The drugmaker also granted underwriters a 30-day option to buy up to 1,098,750 more ADSs at the IPO price, with underwriting costs deducted.
J.P. Morgan Securities and Citigroup Global Markets served as the joint book-running managers for the offering.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。